Clinical Study
Influence of Age and Neurotoxic HAART Use on Frequency of HIV Sensory Neuropathy
Table 2
Relationship between demographic and clinical variables and the occurrence of HIV-sensory neuropathy.
| Variables | SN present
| SN absent
| value |
| Mean age ± SD, years | | | 0.03 | Male () | 48 (45.7%) | 57 (54.3%) | 0.09 | Female () | 78 (35.8%) | 140 (64.2%) | Mean height ± SD, metres | | | 0.15 | HAART treated () | 60 (42.3%) | 82 (57.7%) | 0.29 | HAART naïve () | 66 (36.5%) | 115 (63.5%) | Mean duration of HAART ± SD, months* | | | 0.59 | Stavudine-based HAART () | 10 (83.3%) | 2 (16.7%) | 0.003** | Non-stavudine-based HAART () | 50 (38.5%) | 80 (61.5%) | Mean CD4 count ± SD, cells/mm3 | | | 0.002 | Median CD4 count ± SD, cells/mm3 | 165.5 | 185.0 | | CD4 count ≤ 200, cells/mm3 () | 74 (42.0%) | 102 (58.0%) | 0.22 | CD4 count >200, cells/mm3 () | 52 (35.4%) | 95 (64.6%) |
|
|
*Duration of therapy for the 142 participants on HAART therapy. **Fisher’s exact value.
|